ACCORD 2
A multicentre, seamless, Phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients.
Type: Interventional
Site and lead:
- Oxford Road Campus: Dr Maya Buch
- Wythenshawe Hospital: Dr Alexander Horsley
Patient group: All COVID-19 patients
Intervention:
- Bemcentinib
Funder: Not available
Sponsor: University Hospital Southampton NHS Foundation Trust
- ACCORD 2 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
- Read our news story about our first patient recruited to ACCORD 2
More about ACCORD-2
This adaptive platform study is designed to rapidly assess multiple candidate agents as treatments for COVID 19. The plan is to add candidate agents as they are identified, and to remove therapies once they have completed their evaluation.
